AKT1 and non-small cell lung carcinoma: Both in vitro and in vivo studies in human NSCLC xenografts have confirmed that by the inhibition of both AKT and mitogen-activated protein kinases signaling pathways, nintedanib resulted in the inhibition of cell proliferation, apoptosis in endothelial cells, and the cell types involved in angiogenesis [74].